Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Kian Behbakht

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-OB/GYN GONC GENERAL OPS
Phone303/724-2066

    Collapse Research 
    Collapse research activities and funding
    R01CA124545     (THORBURN, ANDREW M)Aug 1, 2008 - May 31, 2012
    NIH
    TRAIL Receptor Signaling in Human Tumors
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Yamamoto TM, Webb PG, Davis DM, Baumgartner HK, Woodruff ER, Guntupalli SR, Neville M, Behbakht K, Bitler BG. Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Mol Cancer Ther. 2022 04 01; 21(4):647-657. PMID: 35373300.
      View in: PubMed
    2. Haag J, Sanders BE, Walker Keach J, Lefkowits C, Sheeder J, Behbakht K. Impact of blinding interviewers to written applications on ranking of Gynecologic Oncology fellowship applicants from groups underrepresented in medicine. Gynecol Oncol Rep. 2022 Feb; 39:100935. PMID: 35141387.
      View in: PubMed
    3. Clauset A, Behbakht K, Bitler BG. Decoding the dynamic tumor microenvironment. Sci Adv. 2021 06; 7(23). PMID: 34088677.
      View in: PubMed
    4. Essel KG, Behbakht K, Lai T, Hand L, Evans E, Dvorak J, Ding K, Konecny G, Moore KN. PARPi after PARPi in epithelial ovarian cancer. Gynecol Oncol Rep. 2021 Feb; 35:100699. PMID: 33537389.
      View in: PubMed
    5. Corr BR, Moroney M, Sheeder J, Eckhardt SG, Sawyer B, Behbakht K, Diamond JR. Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials. Cancer. 2020 10 01; 126(19):4289-4293. PMID: 32697381.
      View in: PubMed
    6. Ross ME, Scott S, Behbakht K, Harper T. Spontaneous dichorionic-diamniotic twins in a noncommunicating uterine horn: A case report. Case Rep Womens Health. 2020 Apr; 26:e00177. PMID: 32055454.
      View in: PubMed
    7. Watson ZL, Yamamoto TM, McMellen A, Kim H, Hughes CJ, Wheeler LJ, Post MD, Behbakht K, Bitler BG. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clin Epigenetics. 2019 11 27; 11(1):165. PMID: 31775874.
      View in: PubMed
    8. O'Cearbhaill RE, Deng W, Chen LM, Lucci JA, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):393-399. PMID: 31653510.
      View in: PubMed
    9. Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations. Mol Cancer Ther. 2020 02; 19(2):602-613. PMID: 31575654.
      View in: PubMed
    10. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw. 2019 08 01; 17(8):896-909. PMID: 31390583.
      View in: PubMed
    11. Adams CL, Dimitrova I, Post MD, Gibson L, Spillman MA, Behbakht K, Bradford AP. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma. Exp Mol Pathol. 2019 10; 110:104284. PMID: 31301306.
      View in: PubMed
    12. Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog. 2019 10; 58(10):1770-1782. PMID: 31219654.
      View in: PubMed
    13. Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, Fisher C, Lefkowits C, Guntupalli SR, Behbakht K, Corr BR. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol. 2019 06; 153(3):517-520. PMID: 30910249.
      View in: PubMed
    14. Breed C, Hicks DA, Webb PG, Galimanis CE, Bitler BG, Behbakht K, Baumgartner HK. Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel. Mol Cancer Res. 2019 03; 17(3):741-750. PMID: 30606772.
      View in: PubMed
    15. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):e183773. PMID: 30347019.
      View in: PubMed
    16. Rauh-Hain JA, Brewster WR, Behbakht K. Society of Gynecologic Oncology 2018 Annual Meeting on Women's Cancer: Meeting report. Gynecol Oncol. 2018 11; 151(2):e7-e9. PMID: 30146111.
      View in: PubMed
    17. Ramzan AA, Behbakht K, Corr BR, Sheeder J, Guntupalli SR. Minority Race Predicts Treatment by Non-gynecologic Oncologists in Women with Gynecologic Cancer. Ann Surg Oncol. 2018 Nov; 25(12):3685-3691. PMID: 30105439.
      View in: PubMed
    18. Behbakht K, Cohn DE, Straughn JM. Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer. Gynecol Oncol. 2018 10; 151(1):4-5. PMID: 30068488.
      View in: PubMed
    19. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29037806.
      View in: PubMed
    20. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29122619.
      View in: PubMed
    21. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30478317.
      View in: PubMed
    22. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 27720204.
      View in: PubMed
    23. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 28608985.
      View in: PubMed
    24. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 24505259.
      View in: PubMed
    25. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 24708919.
      View in: PubMed
    26. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 26542594.
      View in: PubMed
    27. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 26731726.
      View in: PubMed
    28. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 18760451.
      View in: PubMed
    29. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 8875917.
      View in: PubMed
    30. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 9579428.
      View in: PubMed
    31. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22333994.
      View in: PubMed
    32. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21363923.
      View in: PubMed
    33. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21264287.
      View in: PubMed
    34. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21997170.
      View in: PubMed
    35. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 8942498.
      View in: PubMed
    36. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 8750508.
      View in: PubMed
    37. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 18266821.
      View in: PubMed
    38. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21996746.
      View in: PubMed
    39. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 8942827.
      View in: PubMed
    40. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 11704223.
      View in: PubMed
    41. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21605894.
      View in: PubMed
    42. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 11277647.
      View in: PubMed
    43. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 31292831.
      View in: PubMed
    44. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 32198139.
      View in: PubMed
    45. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 32589230.
      View in: PubMed
    46. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 32641392.
      View in: PubMed
    47. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 32928797.
      View in: PubMed
    48. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 33545690.
      View in: PubMed
    49. Zhou K, Spillman MA, Behbakht K, Komatsu JM, Abrahante JE, Hicks D, Schotl B, Odean E, Jones KL, Graner MW, Bemis LT. A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis. Anal Biochem. 2017 11 01; 536:8-15. PMID: 28803886.
      View in: PubMed
    50. Guntupalli SR, Sheeder J, Ioffe Y, Tergas A, Wright JD, Davidson SA, Behbakht K, Flink DM. Sexual and Marital Dysfunction in Women With Gynecologic Cancer. Int J Gynecol Cancer. 2017 03; 27(3):603-607. PMID: 28129243.
      View in: PubMed
    51. Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017 04; 15(4):382-394. PMID: 28108622.
      View in: PubMed
    52. Hicks DA, Galimanis CE, Webb PG, Spillman MA, Behbakht K, Neville MC, Baumgartner HK. Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration. BMC Cancer. 2016 10 11; 16(1):788. PMID: 27724921.
      View in: PubMed
    53. Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer. Gynecol Oncol. 2016 Nov; 143(2):319-325. PMID: 27640961.
      View in: PubMed
    54. Osborne RJ, Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, Spirtos NM, Chan JK, Tidy JA, Miller DS. Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. Obstet Gynecol. 2016 Sep; 128(3):535-542. PMID: 27500329.
      View in: PubMed
    55. Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 09; 14(9):1134-63. PMID: 27587625.
      View in: PubMed
    56. Corr BR, Breed C, Sheeder J, Weisdack S, Behbakht K. Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy? Gynecol Oncol Rep. 2016 Aug; 17:65-8. PMID: 27617286.
      View in: PubMed
    57. Blake EA, Sheeder J, Behbakht K, Guntupalli SR, Guy MS. Factors Impacting Use of Robotic Surgery for Treatment of Endometrial Cancer in the United States. Ann Surg Oncol. 2016 10; 23(11):3744-3748. PMID: 27172774.
      View in: PubMed
    58. Jarrett MJ, Vázquez-Torres A, Frank DN, McCollister BD, Henthorn PK, Ir D, Sheeder J, Guy MS, Anwar HQ, Behbakht K. Influence of Gelatin-Thrombin Matrix Tissue Sealant on Bacterial Colony Formation and Risk of Pelvic Infection. Infect Dis Obstet Gynecol. 2016; 2016:2649708. PMID: 27199534.
      View in: PubMed
    59. Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Apr; 141(1):43-8. PMID: 27016228.
      View in: PubMed
    60. Guy MS, Sheeder J, Behbakht K, Wright JD, Guntupalli SR. Comparative outcomes in older and younger women undergoing laparotomy or robotic surgical staging for endometrial cancer. Am J Obstet Gynecol. 2016 Mar; 214(3):350.e1-350.e10. PMID: 26433173.
      View in: PubMed
    61. Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2015 Nov; 25(9):1565-73. PMID: 26495758.
      View in: PubMed
    62. Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):614-9. PMID: 26144601.
      View in: PubMed
    63. Goldstein CL, Susman E, Lockwood S, Medlin EE, Behbakht K. Awareness of symptoms and risk factors of ovarian cancer in a population of women and healthcare providers. Clin J Oncol Nurs. 2015 Apr; 19(2):206-12. PMID: 25840386.
      View in: PubMed
    64. Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015 Apr 01; 33(10):1180-5. PMID: 25713428.
      View in: PubMed
    65. Doo DW, Guntupalli SR, Corr BR, Sheeder J, Davidson SA, Behbakht K, Jarrett MJ, Guy MS. Comparative Surgical Outcomes for Endometrial Cancer Patients 65 Years Old or Older Staged With Robotics or Laparotomy. Ann Surg Oncol. 2015 Oct; 22(11):3687-94. PMID: 25672563.
      View in: PubMed
    66. Anderson CK, Medlin E, Ferriss AF, Sheeder J, Davidson S, Gibbs R, Behbakht K, Guntupalli SR. Association between gelatin-thrombin matrix use and abscesses in women undergoing pelvic surgery. Obstet Gynecol. 2014 Sep; 124(3):589-595. PMID: 25162261.
      View in: PubMed
    67. Ney DE, Messersmith W, Behbakht K. Anti-ma2 paraneoplastic encephalitis in association with recurrent cervical cancer. J Clin Neurol. 2014 Jul; 10(3):262-6. PMID: 25045381.
      View in: PubMed
    68. Guy MS, Cheng G, Post MD, Spillman MA, Behbakht K, Davidson S, Sheeder J, Guntupalli SR. Outcomes of women with atypical glandular cells on preoperative cytology and endometrial cancer. Int J Gynecol Cancer. 2014 Feb; 24(2):266-71. PMID: 24401985.
      View in: PubMed
    69. Corr BR, Behbakht K, Spillman MA. Gynecologic biopsy for molecular profiling: a review for the interventional radiologist. Semin Intervent Radiol. 2013 Dec; 30(4):417-24. PMID: 24436571.
      View in: PubMed
    70. Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA. Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer. 2013 Mar; 23(3):417-21. PMID: 23385282.
      View in: PubMed
    71. Sholl AB, Aisner DL, Behbakht K, Post MD. Novel TP53 gene mutation and correlation with p53 immunohistochemistry in a mixed epithelial carcinoma of the endometrium. Gynecol Oncol Case Rep. 2012; 3:11-3. PMID: 24371653.
      View in: PubMed
    72. Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer. 2013 Jan; 49(1):121-31. PMID: 22921155.
      View in: PubMed
    73. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. 2013 Mar 14; 32(11):1341-50. PMID: 22580613.
      View in: PubMed
    74. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Oct; 123(1):19-26. PMID: 21752435.
      View in: PubMed
    75. de la Garza J, Wilson SS, Behbakht K. Total pelvic exenteration with a split-thickness skin graft neovagina, continent orthotopic neobladder and rectal reanastomosis, resulting in no external ostomies and adequate sexual function. Gynecol Oncol. 2009 Nov; 115(2):312-3. PMID: 19665216.
      View in: PubMed
    76. Qamar L, Davis R, Anwar A, Behbakht K. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model. Gynecol Oncol. 2008 Sep; 110(3):425-31. PMID: 18619662.
      View in: PubMed
    77. Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat. 2008 Feb-Apr; 11(1-2):17-24. PMID: 18374623.
      View in: PubMed
    78. Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A, Ford HL. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res. 2007 Apr 01; 67(7):3036-42. PMID: 17409410.
      View in: PubMed
    79. Lyle P, Evans R, Jarboe E, Fong D, Behbakht K, Davidson S, Singh M. Biphasic tumors of the female genital tract. Oncology (Williston Park). 2005 Aug; 19(9):1178, 1183, 1188, 1190, 1195-6 passim. PMID: 16255134.
      View in: PubMed
    80. Behbakht K, Lynch A, Teal S, Degeest K, Massad S. Social and cultural barriers to Papanicolaou test screening in an urban population. Obstet Gynecol. 2004 Dec; 104(6):1355-61. PMID: 15572502.
      View in: PubMed
    81. Massad LS, Behbakht K, Collins YC, Cejtin HE. Histologic findings from the cervix among older women with abnormal cervical cytology. Gynecol Oncol. 2003 Mar; 88(3):340-4. PMID: 12648584.
      View in: PubMed
    82. Behbakht K, Friedman J, Heimler I, Aroutcheva A, Simoes J, Faro S. Role of the vaginal microbiological ecosystem and cytokine profile in the promotion of cervical dysplasia: a case-control study. Infect Dis Obstet Gynecol. 2002; 10(4):181-6. PMID: 12648311.
      View in: PubMed
    83. Aroutcheva AA, Simoes JA, Behbakht K, Faro S. Gardnerella vaginalis isolated from patients with bacterial vaginosis and from patients with healthy vaginal ecosystems. Clin Infect Dis. 2001 Oct 01; 33(7):1022-7. PMID: 11528575.
      View in: PubMed
    84. van der Heijden O, Chiu HC, Park TC, Takahashi H, LiVolsi VA, Risinger JI, Barrett JC, Berchuck A, Evans AC, Behbakht K, Menzin AW, Liu PC, Benjamin I, Morgan MA, King SA, Rubin SC, Boyd J. Allelotype analysis of uterine leiomyoma: localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q. Mol Carcinog. 1998 Dec; 23(4):243-7. PMID: 9869453.
      View in: PubMed
    85. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998 Aug; 70(2):255-8. PMID: 9740700.
      View in: PubMed
    86. Bandera CA, Takahashi H, Behbakht K, Liu PC, LiVolsi VA, Benjamin I, Morgan MA, King SA, Rubin SC, Boyd J. Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma. Cancer Res. 1997 Feb 01; 57(3):513-5. PMID: 9012483.
      View in: PubMed
    87. Takahashi H, Chiu HC, Bandera CA, Behbakht K, Liu PC, Couch FJ, Weber BL, LiVolsi VA, Furusato M, Rebane BA, Cardonick A, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC, Boyd J. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res. 1996 Jun 15; 56(12):2738-41. PMID: 8665505.
      View in: PubMed
    88. Behbakht K, DeGeest K, Turyk ME, Wilbanks GD. All-trans-retinoic acid inhibits the proliferation of cell lines derived from human cervical neoplasia. Gynecol Oncol. 1996 Apr; 61(1):31-9. PMID: 8626114.
      View in: PubMed
    89. Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber BL, Friedman LS, King MC, Furusato M, LiVolsi VA, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 1995 Jul 15; 55(14):2998-3002. PMID: 7606717.
      View in: PubMed
    90. King SA, Adas AA, LiVolsi VA, Takahashi H, Behbakht K, McGovern P, Benjamin I, Rubin SC, Boyd J. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer. 1995 Jun 01; 75(11):2700-5. PMID: 7743473.
      View in: PubMed
    91. Behbakht K, Yordan EL, Casey C, DeGeest K, Massad LS, Kirschner CV, Wilbanks GD. Prognostic indicators of survival in advanced endometrial cancer. Gynecol Oncol. 1994 Dec; 55(3 Pt 1):363-7. PMID: 7835775.
      View in: PubMed
    Behbakht's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)